• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Prenat Diagn . Vertical transmission of SARS-CoV2 during pregnancy: A high-risk cohort

tetano

Editor, Senior Moderator
Prenat Diagn


. 2021 Jun 8.
doi: 10.1002/pd.5980. Online ahead of print.
Vertical transmission of SARS-CoV2 during pregnancy: A high-risk cohort


Mariane de Fátima Yukie Maeda[SUP] 1 [/SUP], Maria de Lourdes Brizot[SUP] 1 [/SUP], Maria Augusta B C Gibelli[SUP] 2 [/SUP], Silvia Maria Ibidi[SUP] 2 3 [/SUP], Werther Brunow de Carvalho[SUP] 2 3 [/SUP], Mara Sandra Hoshida[SUP] 1 [/SUP], Clarisse Martins Machado[SUP] 4 [/SUP], Ester Cerdeira Sabino[SUP] 5 [/SUP], Lea Campos de Oliveira da Silva[SUP] 6 [/SUP], Thomas Jaenisch[SUP] 7 8 [/SUP], Maria Cassia Mendes-Correa[SUP] 4 [/SUP], Philippe Mayaud[SUP] 9 [/SUP], Rossana Pulcineli Vieira Francisco[SUP] 1 3 [/SUP], HC-FMUSP-Obstetric COVID19 Study Group



Affiliations

Abstract

Objective: Identify the potential for and risk factors of SARS-CoV-2 vertical transmission.
Methods: Symptomatic pregnant women with COVID-19 diagnosis in whom PCR for SARS-CoV-2 was performed at delivery using maternal serum and at least one of the biological samples: cord blood (CB), amniotic fluid (AF), colostrum and/or oropharyngeal swab (OPS) of the neonate. The association of parameters with maternal, AF and/or CB positivity and the influence of SARS-CoV-2 positivity in AF and/or CB on neonatal outcomes were investigated.
Results: Overall 73.4% (80/109) were admitted in hospital due to COVID-19, 22.9% needed intensive care and there were four maternal deaths. Positive RT-PCR for SARS-CoV-2 was observed in 14.7% of maternal blood, 13.9% of AF, 6.7% of CB, 2.1% of colostrum and 3.7% of OPS samples. The interval between COVID-19 symptoms and delivery was inversely associated with SARS-CoV-2 positivity in the maternal blood (P=0.002) and in the AF and/or CB (P=0.049). Maternal viremia was associated with positivity for SARS-CoV-2 in AF and/or CB (P= 0.001). SARS-CoV-2 positivity in the compartments was not associated with neonatal outcomes.
Conclusion: Vertical transmission is possible in pregnant women with COVID-19 and a shorter interval between maternal symptoms and delivery is an influencing factor. This article is protected by copyright. All rights reserved.

Keywords: COVID-19; SARS-CoV-2; coronavirus disease 2019; fetal development; fetal diseases; pregnancy complcations; vertical/mother-to-child transmission.
 
Back
Top Bottom